Anti- Chlamydia Pneumoniae Antibody (Cpn-IgM) ELISA Kit

Produktnummer ABIN1326821

Produktdetails

Target: Anti- Chlamydia Pneumoniae Antibody (Cpn-IgM)

Reaktivität: Human

Nachweismethode: Colorimetric

Methodentyp: Competition ELISA

Applikation: ELISA

Verwendungszweck: Diluted patient serum (serum diluent contains sorbent to remove rheumatoid factor and human IgG interference) is added to wells coated with purified antigen. IgM specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgM specific antibody in the sample.

Proben: Serum

Analytische Methode: Qualitative

Anwendungsinformationen

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Referenzen

Kumar, Kapoor, Saigal: "Hemorrhagic encephalitis caused by Mycoplasma pneumoniae in an 11-year-old boy: A rare case report." in: Indian journal of medical microbiology, Vol. 33, Issue 3, pp. 463-4, (2015) (PubMed).

Antigendetails

Target: Anti- Chlamydia Pneumoniae Antibody (Cpn-IgM)

Substanzklasse: Antibody

Hintergrund: Chlamydia pneumoniae, the third recognized of five possible species of Chlamydia (trachomatis, psittaci, pneumoniae, pecorum and an as-yet-unnamed species) was formerly known as Chlamydia spp. Strain TWAR.This respiratory pathogen which causes acute respiratory disease, pneumonia and pharyngitis is often isolated from patients with otitis media with effusion, pneumonia with pleural effusion and in asymptomatic respiratory tract infections. C. ipneuomoniaei causes up to 10% of community-acquired pneumonia cases and it is also a risk factor for coronary heart disease and Guillain-Barr_ syndrome. Seroprevalence of C.ipneumoniaei among children is low and increases sharply in teenagers, continues to increase until middle age, and remains high (50%) into old age, suggesting that most people have more than one C.ipneumoniaei infection during their lifetime. Primary chlamydial infection is characterized by a predominant IgM response within 2 to 4 weeks and a delayed IgG and IgA response within 6 to 8 weeks. After acute C.ipneumoniae iinfection, IgM antibodies are usually lost within 2 to 6 months IgG antibody titers rise and usually decrease slowly whereas IgA antibodies tend to disappear rapidly. When primary chlamydia infection is suspected, the detection of IgM is highly diagnostic. In reinfection, IgM level may be rarely detected while IgG and IgA levels rise quickly, often in one to two weeks. IgA antibodies have shown to be a reliable immunological marker of primary, chronic and recurrent infections. These antibodies usually decline rapidly to baseline levels following treatment and eradication of the chlamydia infections.